Inflammatory bowel disease (IBD)
Conditions
Interventions
Peripheral nerve injury group:NA
Tolerant Group:NA
Sponsors
Shenzhen Children’s Hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1. Eligible patients were newly diagnosed or previously diagnosed pediatric patients with inflammatory bowel disease (IBD) confirmed at the Department of Gastroenterology, Shenzhen Children's Hospital, or those previously diagnosed according to the Lennard-Jones criteria and classified according to the Montreal classification; 2. Planning to take or currently taking thalidomide;
Exclusion criteria
Exclusion criteria: 1. Active Tuberculosis; 2. Malignant tumors; 3. children complicated by septicemia or requiring immediate surgery; 4. with significant abnormalities in the pulmonary, renal, hepatic, cardiac, hematologic, or neurological systems;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thalidomide induced Peripheral Neuropathy; | — |
Secondary
| Measure | Time frame |
|---|---|
| SNP mutation status of candidate genes;Plasma endogenous small-molecule metabolite levels;Therapeutic effect of thalidomide; | — |
Countries
China
Contacts
Public ContactJing Mao
Shenzhen Children’s Hospital
Outcome results
None listed